May 2025 Psychedelic Patent Update: Gilgamesh expands Phase 2a lead candidate moat, Lykos files continuation apps, Reconnect enters crowded 5-MeO-DMT IP

Psychedelic Alpha’s May 2025 patent update reports 17 PCTs and 34 US psychedelic-focused patent applications added to its tracker, alongside a selective set of patent actions. Gilgamesh Pharmaceuticals is highlighted for broadening its competitive moat around a lead tryptamine candidate after a positive Phase 2a readout, signaling increased IP protection around the drug program. Lykos Therapeutics is noted for publishing further continuation applications, reflecting ongoing strategy to extend and refine its patent position. Reconnect Labs is featured as it joins a crowded 5-MeO-DMT patent landscape, with the bulletin framing these filings as part of intensifying competition for ownership of key psychedelic drug and formulation IP.